General description
INN
Cladribine
Medicine type
Chemical agent
EML status history
First added in 2023
(TRS
1049)
for
Multiple sclerosis
Application rejected in 2023
(TRS
1049)
for
Langerhans cell histiocytosis
Wikipedia
DrugBank
Recommendations
Section
Medicines for multiple sclerosis
- Oral > Solid > tablet: 10 mg
Indications
Section
Cytotoxic medicines
- Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial
Indications